Active metabolite from Tamiflu super([registered]) solution is bioequivalent to that from capsule delivery in healthy volunteers: A cross-over, randomised, open-label study

The bioavailability of oseltamivir phosphate and oseltamivir carboxylate were assessed in healthy volunteers when delivered as a solution of the active pharmaceutical ingredient (API) compared with the commercial capsule formulation. The 90% confidence intervals (CIs) for the ratios of the two treat...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2006-11, Vol.24 (44-46), p.6660-6663
Main Authors: Brewster, M, Smith, J R, Dutkowski, R, Robson, R
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The bioavailability of oseltamivir phosphate and oseltamivir carboxylate were assessed in healthy volunteers when delivered as a solution of the active pharmaceutical ingredient (API) compared with the commercial capsule formulation. The 90% confidence intervals (CIs) for the ratios of the two treatments (capsule versus solution) were within the reference region [0.80- 1.25] for area under the curve (AUC sub(0-infinity): [0.94-0.99]) and maximum observed plasma concentrations (C sub(max): [0.93-1.08]). Thus, the two formulations were bioequivalent for oseltamivir carboxylate. For pandemic stockpiling of Tamiflu super([registered]), governments can therefore choose between the capsule formulation alone, the API alone, or quantities of both.
ISSN:0264-410X
DOI:10.1016/j.vaccine.2006.05.080